ATE108068T1 - Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. - Google Patents

Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.

Info

Publication number
ATE108068T1
ATE108068T1 AT88115607T AT88115607T ATE108068T1 AT E108068 T1 ATE108068 T1 AT E108068T1 AT 88115607 T AT88115607 T AT 88115607T AT 88115607 T AT88115607 T AT 88115607T AT E108068 T1 ATE108068 T1 AT E108068T1
Authority
AT
Austria
Prior art keywords
hiv
infected
heteroconjugates
killing
antibody
Prior art date
Application number
AT88115607T
Other languages
English (en)
Inventor
Joyce M Zarling
Jeffrey A Ledbetter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE108068T1 publication Critical patent/ATE108068T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT88115607T 1987-09-23 1988-09-22 Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. ATE108068T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10015787A 1987-09-23 1987-09-23

Publications (1)

Publication Number Publication Date
ATE108068T1 true ATE108068T1 (de) 1994-07-15

Family

ID=22278371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88115607T ATE108068T1 (de) 1987-09-23 1988-09-22 Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.

Country Status (8)

Country Link
EP (1) EP0308936B1 (de)
JP (1) JP2755395B2 (de)
AT (1) ATE108068T1 (de)
AU (1) AU629180B2 (de)
CA (1) CA1338518C (de)
DE (1) DE3850542T2 (de)
ES (1) ES2058199T3 (de)
HK (1) HK110594A (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
CA2062795A1 (en) * 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
EP0553244B8 (de) * 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
CA2063035A1 (en) * 1991-03-27 1992-09-28 Klaus Karjalainen Chimaeric antibodies containing the ligand domain of cd4
EP0580758A4 (de) * 1991-04-18 1995-04-05 Sinai School Medicine Rekombinante antikörper gegen menschlichen immunschwächevirus.
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU740227B2 (en) 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
PT1650219E (pt) 1997-10-17 2008-03-31 Genentech Inc Homólogos de toll humana
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
EP1037927B1 (de) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
ES2313778T3 (es) 1998-03-17 2009-03-01 Genentech, Inc. Polipeptidos homologos de vegf y de bmp1.
CA2328498A1 (en) 1998-06-12 1999-12-16 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same____________________________________
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1820859B9 (de) 1998-12-22 2009-10-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200479B1 (de) 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Mehrere zytokin-antikörper komplexen
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
CA2633595A1 (en) 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
DK1472275T3 (da) 2002-02-05 2009-04-14 Genentech Inc Proteinoprensning
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1572748B1 (de) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
CA2519870A1 (en) 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
PL1636593T3 (pl) 2003-06-06 2009-08-31 Genentech Inc Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
CA2546285C (en) 2003-11-17 2015-12-29 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP2008502317A (ja) 2003-12-30 2008-01-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Ｉｌ−７融合タンパク質
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
EA016429B1 (ru) 2005-12-30 2012-04-30 Мерк Патент Гмбх Антитела против cd19 с пониженной иммуногенностью
SI1966238T1 (sl) 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
EP1982181B1 (de) 2006-02-06 2010-12-15 Rhode Island Hospital Gpr30-östrogenrezeptor bei mammakarzinomen
AU2007297565A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
SG196798A1 (en) 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
PL2462158T3 (pl) 2009-08-06 2018-05-30 F. Hoffmann-La Roche Ag Sposób poprawy usuwania wirusów przy oczyszczaniu białka
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
MX368790B (es) 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102985437B (zh) 2010-05-28 2016-05-25 弗·哈夫曼-拉罗切有限公司 通过下调ldh和pdhk表达降低乳酸水平和增加多肽生产
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014078729A1 (en) 2012-11-15 2014-05-22 Genentech, Inc. IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY
RU2019120404A (ru) 2013-03-13 2019-08-06 Дженентек, Инк. Составы антител
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
US9908938B2 (en) 2013-03-14 2018-03-06 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
EP3712252A1 (de) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Zellkulturzusammensetzungen mit antioxidantien und verfahren zur polypeptidherstellung
WO2014169076A1 (en) 2013-04-09 2014-10-16 Annexon,,Inc. Methods of treatment for neuromyelitis optica
EP3019523A4 (de) 2013-07-09 2016-12-28 Annexon Inc Verfahren zur behandlung von morbus alzheimer und morbus huntington
JP6462681B2 (ja) 2013-07-12 2019-01-30 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィーのインプットの最適化の解明
MX2016002798A (es) 2013-09-05 2016-07-21 Genentech Inc Metodo para reutilizacion de cromatografia.
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
ES2761675T3 (es) 2014-05-30 2020-05-20 Henlix Biotech Co Ltd Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
MX2017003121A (es) 2014-09-15 2017-08-02 Genentech Inc Formulaciones de anticuerpos.
JP6932639B2 (ja) 2014-09-29 2021-09-08 デューク ユニバーシティ Ｈｉｖ‐１エンベロープ標的化アームを備える二重特異性分子
JP6770966B2 (ja) 2014-11-05 2020-10-21 ジェネンテック， インコーポレイテッド 細菌における２鎖タンパク質の生成方法
SG10202008810QA (en) 2014-11-05 2020-10-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
EP3991748A3 (de) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin-antikörper und verfahren zur verwendung davon
CA2987403A1 (en) 2015-05-28 2016-12-01 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
KR20180013881A (ko) 2015-05-29 2018-02-07 제넨테크, 인크. 암에서의 pd-l1 프로모터 메틸화
EP3307771A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3341411A1 (de) 2015-08-28 2018-07-04 Alector LLC Anti-siglec-7-antikörper und verfahren zur verwendung davon
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
AU2016343987B2 (en) 2015-10-29 2023-11-23 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
CN108472379B (zh) 2015-12-30 2022-06-21 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
JP7438662B2 (ja) 2016-01-25 2024-02-27 ジェネンテック， インコーポレイテッド Ｔ細胞依存性二重特異的抗体をアッセイするための方法
RS64771B1 (sr) 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
CN109476732B (zh) 2016-04-13 2024-03-22 赛诺菲 三特异性和/或三价结合蛋白
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
EP3497440A1 (de) 2016-08-15 2019-06-19 H. Hoffnabb-La Roche Ag Chromatographieverfahren zur quantifizierung eines nichtionischen tensids in einer zusammensetzung mit dem nichtionischen tensid und einem polypeptid
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
KR102646046B1 (ko) 2017-01-06 2024-03-08 바이오션, 인코포레이티드 Erbb2 항체 및 이의 용도
CN110741019A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 特异性识别磷脂酰肌醇蛋白聚糖3的构筑体及其用途
EP3625258A1 (de) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5-antikörper und verfahren zur verwendung davon
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3694882A2 (de) 2017-10-10 2020-08-19 Sanofi Anti-cd38 antikörper und kombinationen mit anti-cd3- und anti-cd28-antikörpern
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
EP3765005A4 (de) 2018-03-13 2022-02-23 The Regents of the University of California Inhibitoren von integrin alpha 2 beta 1 und verfahren zur verwendung
AU2019282778A1 (en) 2018-06-08 2020-12-10 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
BR112021001451A2 (pt) 2018-07-27 2021-04-27 Alector Llc anticorpos monoclonais anti-siglec-5 isolados, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, composição farmacêutica e métodos para induzir ou promover a sobrevida, para diminuir a atividade, para diminuir os níveis celulares, para induzir a produção de espécies reativas, para induzir a formação de neutrophil extracellular trap (net), para induzir a ativação de neutrófilos, para atenuar um ou mais neutrófilos imunossuprimidos e para aumentar a atividade de fagocitose
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3864043A1 (de) 2018-10-09 2021-08-18 Sanofi Trispezifische anti-cd38-, anti-cd28- und anti-cd3-bindende proteine und verfahren zur verwendung bei der behandlung von virusinfektionen
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
EP3956664A1 (de) 2019-04-18 2022-02-23 Genentech, Inc. Antikörperpotenztest
JP2023506014A (ja) 2019-12-12 2023-02-14 アレクトル エルエルシー 抗ｃｄ３３抗体の使用方法
EP4142707A1 (de) 2020-05-01 2023-03-08 The Regents of the University of California Inhibitoren von alpha-2-beta-1-integrin und verfahren zur verwendung davon
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023245105A1 (en) 2022-06-17 2023-12-21 Genentech, Inc. Use of kosmotropes to enhance yield of an affinity chromatography purification step

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES521370A0 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
ATE74622T1 (de) * 1984-10-31 1992-04-15 Massachusetts Inst Technology Verfahren zum sensibilisieren einer zielzelle zum lysen durch cytotoxische t-lymphkoerperchen.
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies

Also Published As

Publication number Publication date
JP2755395B2 (ja) 1998-05-20
AU629180B2 (en) 1992-10-01
AU2279988A (en) 1989-03-23
EP0308936B1 (de) 1994-07-06
DE3850542T2 (de) 1994-11-24
DE3850542D1 (de) 1994-08-11
EP0308936A3 (en) 1990-02-14
JPH01163134A (ja) 1989-06-27
ES2058199T3 (es) 1994-11-01
CA1338518C (en) 1996-08-13
HK110594A (en) 1994-10-21
EP0308936A2 (de) 1989-03-29

Similar Documents

Publication Publication Date Title
ATE108068T1 (de) Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
BR0114036A (pt) Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
DE69833160D1 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
DE239425T1 (de) Zum hervorrufen von aids geeigneter retrovirus vom typ hiv-2, sowie seine antigen- und nukleinsaeure-bestandteile.
BR0008741A (pt) Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv
DE69106493D1 (de) Sulfonische Stilbenderivate zur Behandlung von Viruserkrankungen.
DE69318136D1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
ATE198354T1 (de) Protein aufspüren auf hiv virion auf basis von hiv-1 vpr fusionmolekulen
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
DE3872754D1 (de) Nachweis von antikoerpern humaner immundefizienz-viren.
DK0554389T3 (da) Molekylære kloner af HIV-1 og anvendelse deraf
DE69230643D1 (de) Methode zur behandlung von viralen infektionen
NO883834L (no) Nye hiv-proteiner og peptider anvendelige i diagnosen, profylaksen eller terapien av aids.
DE69003408D1 (de) Sulfatierte Vinylpolymere in Präparaten zur Behandlung von retroviralen Infektionen.
NO970158L (no) Difluorstaton-antivirale midler
DE69230491D1 (de) Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
ES2058259T3 (es) Antigenos sinteticos para la deteccion de enfermedad relacionada con sida causada por lav-2.
EP0323157A3 (de) Antivirale Verbindungen und Methoden
BR9611588A (pt) Utilização da flupirtina na profilaxia e terapia de doenças associadoas com danos ao sistema celular hematopoiético
ATE88752T1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
Van Den Heuvel et al. Isolation of a bovine plasma fibronectin-containing complex which inhibits the expression of bovine leukemia virus p24
Hart et al. A comparison of polymerase chain reaction and an infectivity assay for human immunodeficiency virus type 1 titration during virus inactivation of blood components
RU94020017A (ru) Способ прогнозирования течения вич-инфекции
RU2097427C1 (ru) Способ инактивации вируса спида

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee